Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynavax Technologies, a clinical-stage biopharmaceutical company, has received a $17 million contract to develop its advanced immunostimulatory sequences technology using Toll-Like Receptor 9 agonists as vaccine adjuvants.
Subscribe to our email newsletter
This five-year contract was awarded by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to develop novel vaccine adjuvant candidates that signal through receptors of the innate immune system.
The contract supports adjuvant development for anthrax as well as other disease models. NIAID is funding 100% of the total $17 million cost of Dynavax’s program.
Dino Dina, president and CEO of Dynavax, said: “This NIH contract award is highly synergistic with our in-house efforts to develop novel adjuvant formulations for clinical use. The funding from this contract, as well as from the NIH grants for our universal flu vaccine program, enables us to devote significant resources to advance our vaccine programs into clinical development.”